59 research outputs found
PHP61 Integration of Cost–Effectiveness Assessment in the Market Access Scheme of Drugs and Medical Devices In France
Antithymocyte Globulins (ATG) As Part Of The Myeloablative Conditioning (MAC) Regimen Can Reduce The Risk Of Severe Graft-Vs.-Host Disease (GVHD) After Allogeneic Stem Cell Transplantation (allo-SCT) From Matched-Unrelated Donors (MUD) [A SFGM-TC Study]
Integration of Cost–Effectiveness Assessment in the Market Access Scheme of Drugs and Medical Devices In France
Multiple myeloma treatment at relapse after autologous stem cell transplantation: a practical analysis
International audienceOver the past decade, significant advances have been made in the field of multiple myeloma. Introduction of the so-called novel agents, proteasome inhibitors (PI) and immunomodulatory drugs (IMiD), and improved supportive care have resulted in significantly better outcome. Standard first line treatment in fit patients include PI and IMiD based induction, high dose melphalan with autologous hematopoietic stem cell transplantation (ASCT) and consolidation/maintenance. However, despite these progresses MM remains incurable for the majority of patients and most patients will relapse. Next generation PI (carfilzomib, ixazomib) and IMiD (pomalidomide) and new therapeutic classes: monoclonal antibody (elotuzumab, daratumumab) and pan-deacetylase inhibitors (panobinostat) have been successfully evaluated in relapse multiple myeloma. Some of these new agents are now approved for multiple myeloma treatment at relapse. However choosing the most appropriate treatment at relapse may be difficult. This review sum up the most important studies and provide evidence to choose the most relevant therapeutic strategy for relapse after ASCT, based on disease, patient and previous treatment related parameters
AUTOGRAFT USING PERIPHERAL BLOOD STEM CELLS COLLECTED AFTER HIGH DOSE MELPHALAN IN HIGH RISK MULTIPLE MYELOMA
Exploring Uncertainty in Economic Evaluation Of Medicines: A Review of The First Manufacturers' Submissions To the French National Authority For Health (Has)
Secondary Acute non Lymphoid Leukemia in Patients Treated for non Hodgkin's Lymphoma: No Risk of Therapy-Related Anll after Provecip Schedule
The addition of liposomal doxorubicin to bortezomib, thalidomide and dexamethasone significantly improves clinical outcome of advanced multiple myeloma
Fixed-dose single agent pegfilgrastim for peripheral blood progenitor cell mobilisation in patients with multiple myeloma
- …